On May 31, 2022 Shanghai Hansoh Pharma reported that published positive results from a China Phase III trial of its third-gen EGFR-TKI inhibitor in the Journal of Clinical Oncology (Press release, Jiangsu Hansoh Pharmaceutical, MAY 31, 2022, View Source [SID1234615397]). Hansoh’s Amelie (aumolertinib mesylate tablets) was administered as a first-line therapy for NSCLC. It significantly out-performed AstraZeneca’s Iressa (gefitinib), especially among patients with brain metastases. Hansoh, which developed Amelie in-house, said it was the first publication of clinical data from a China-originated third-generation EGFR-TKI in the official ASCO (Free ASCO Whitepaper) journal. Hanson out-licensed ex-China rights for the drug to EQRx

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!